Basilea Pharmaceutica AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BPMUF research report →
Price Chart
About the company
Basilea Pharmaceutica AG is a biopharmaceutical company already generating revenue from its products, which are designed to fulfill medical needs in the challenging areas of cancer (oncology) and infectious diseases (anti-infectives). The company's product portfolio includes Cresemba, an azole antifungal drug administered intravenously or orally. This medication is approved for treating invasive aspergillosis and mucormycosis in both the United States and the European Union.
- CEO
- David Veitch
- IPO
- 2015
- Employees
- 189
- HQ
- Allschwil, BL, CH
Get TickerSpark's AI analysis on BPMUF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $957.95M
- P/E
- 15.40
- Fwd P/E
- 17.02
- PEG
- -1.27
- P/S
- 3.28
- P/B
- 5.00
- EV/EBITDA
- 11.30
- Div Yield
- 0.00%
- Gross Margin
- 87.67%
- Op Margin
- 23.90%
- Net Margin
- 21.15%
- ROE
- 36.06%
- ROIC
- 20.44%
Latest fiscal year · YoY change
- Revenue
- $232.51M+11.5%
- Gross Profit
- $193.19M+13.7%
- Op Income
- $51.62M
- Net Income
- $40.22M-48.2%
- EPS
- $3.29-48.8%
- OCF Growth
- -16.5%
- FCF Growth
- -18.0%
- 52W High
- $77.40
- 52W Low
- $59.29
- 50D MA
- $61.92
- 200D MA
- $65.88
- Beta
- 0.41
- RSI (14)
- 99
- Avg Volume
- 6
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the BPMUF Q2 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 92.0%
- Shares Outstanding
- 12.38M
- Float Shares
- 11.38M
Our BPMUF coverage
Recent articles, reports, and earnings notes.
No research on BPMUF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BPMUF report →Basilea Pharmaceutica AG (BPMUF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 18
Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update
defenseworld.net · Aug 15
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
globenewswire.com · May 28
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
globenewswire.com · Apr 15
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
globenewswire.com · Apr 9
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
globenewswire.com · Mar 23
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
globenewswire.com · Feb 25
Basilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call Transcript
seekingalpha.com · Feb 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.